Fig. 5
Akt and MAPK activities in therapy resistant variants. SKBR3 gefitinib and lapatinib sensitive and resistant cells were lysed and subjected to western blotting for expression and activity of a Akt/p-AktS473, T308, b p44/42 MAPK/p-MAPKT202, Y204 using total or phospho-specific antibodies to the active sites. c, d Average integrated density of p-Akt/Akt (c) or p-P44/42 MAPK/P44/42 MAPK (d), as quantified from Image J analysis of positive bands from western blots. N = 3